Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: Markers for diabetes and cardiovascular risk?

American Heart Journal

Volumn 153, Issue 1, 2007, Pages 67-73

  Anderson, Jeffrey L ^a,b   Carlquist, John F ^a,b   Roberts, William L ^b,c   Horne, Benjamin D ^a   May, Heidi T ^a   Schwarz, Elisabeth L ^c   Pasquali, Marzia ^b,c   Nielson, Rebecca ^c   Kushnir, Mark M ^c   Rockwood, Alan L ^c   Bair, Tami L ^a   Muhlestein, Joseph B ^a,b  

^a LDS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; C REACTIVE PROTEIN; CORTISONE; HYDROCORTISONE; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PREDICTION; PRIORITY JOURNAL;

ARGININE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-PEPTIDE; CASE-CONTROL STUDIES; CORONARY DISEASE; CORTISONE; DIABETES MELLITUS; FEMALE; HUMANS; HYDROCORTISONE; HYPERINSULINISM; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 33845320171     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.10.014     Document Type: Article

References (41)

1. American Diabetes Association. Diabetes vital statistics 1996 (1996) 4 [Alexandria, VA]
2. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997) 1183-1197
3. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease: the Framingham Study. JAMA 241 (1979) 2035-2038
4. Stamler J., Vaccaro O., Neaton J.D., et al. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
5. Folsom A.R., Szklo M., Stevens J., et al. A prospective study of coronary heart disease in relation to fasting insulin, glucose and diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 20 (1997) 935-942
6. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
7. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 33 (2004) 283-303
8. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., et al. Definition of the metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
9. Eckel R.H., Barouch W.W., and Ershow A.G. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the Phathophysiology of Obesity-Associated Cardiovascular Disease. Circulation 105 (2002) 2923-2928
10. Grundy S.M. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 105 (2002) 2696-2698
11. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
12. Haffner S.M., Valdez R.A., Hazuda H.P., et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes Care 41 (1992) 715-722
13. de Vegt F., Dekker J., Jager A., et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 285 (2001) 2109-2113
14. Trevisan M., Liu J., Bahsas F.B., et al. Syndrome X and mortality: a population-based study. Am J Epidemiol 148 (1998) 958-966
15. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
16. Lakka H.-M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
17. Ridker P.M., Buring J.E., Cook N.R., et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107 (2003) 391-397
18. Anderson J.L., Horne B., Reyna S., et al. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease?. Cardiology 101 (2004) 185-193
19. Mensah G.A., Mokdad A.H., Ford E., et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin 22 (2004) 485-504
20. Taylor G.S., Muhlestein J.B., Wagner G.S., et al. Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J 136 (1998) 792-803
21. Pearson T.A., Mensah G., Alexander W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
22. Coutinho M., Gerstein H.C., Wang Y., et al. The relationship between glucose and incident cardiovascular events: a meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 (1999) 233-240
23. Fisman E.Z., Motro M., Tenenbaum A., et al. Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis. Am Heart J 141 (2001) 485-490
24. Hoogwerf B.J., Sprecher D.L., Pearce G.L., et al. Fasting blood glucose in the nondiabetic range is a continuous and graded risk factor for CHD. J Am Coll Cardiol 39 (2002) 221
25. Gerstein H.C., and Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 347 (1996) 949-950
26. Gerstein H.C. Is glucose a continuous risk factor for cardiovascular mortality. Diabetes Care 22 (1999) 659-660
27. Hsieh W.A., and Law R.E. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med 105 (1998) 4S-14S
28. Haffner S.M. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol 84 (1999) 11J-14J
29. Smiley T., Oh P., and Shane L.G. The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes: a systematic review. Can J Cardiol 17 (2001) 797-805
30. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
31. Wingard D.L., Barrett-Connor E., and Ferrara A. Is insulin really a heart disease risk factor?. Diabetes Care 18 (1995) 1299-1304
32. Jiang X., Srinivasan S.R., and Berenson G.S. Relation of obesity to insulin secretion and clearance in adolescents: the Bogalusa Heart Study. Int J Obes Relat Metab Disord 20 (1996) 951-956
33. Relimpio F., Losada F., Pumar A., et al. Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients. Diabetes Res Clin Pract 36 (1997) 173-180
34. Wahren J., Johansson B.L., Wallberg-Henriksson H., et al. C-peptide revisited-new physiological effects and therapeutic implications. J Intern Med 240 (1996) 115-124
35. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 358 (2001) 2096-2097
36. Valkonen V.P., Paiva H., Salonen J.T., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
37. Stuhlinger M.C., Abbasi F., Chu J.W., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287 (2002) 1420-1426
38. Zoccali C., Bode-Boger S.M., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease. Lancet 348 (2001) 2113-2117
39. Homma M., Tanaka A., Hino K., et al. Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and in patients with diabetes mellitus and chronic renal failure. Metabolism 50 (2001) 801-804
40. Masuzaki H., Paterson J., Shinyama H., et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294 (2001) 2166-2170
41. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2005) 1730-1737